Sign in Subscribe

targeted-therapy

A collection of 104 issues

CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells

Skip to content The CRC Digest ◇ RESEARCH CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells Researchers used direct electroporation of Cas9 ribonucleoproteins to achieve allele-specific disruption of KRAS p.G12V in SW480 colorectal cancer cells, assessing delivery efficiency and on-target editing. (Iranian Journal of Basic Medical Sciences) This content

Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models

Skip to content The CRC Digest ◇ RESEARCH Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models A bispecific antibody co-targeting EGFR and cadherin-17 (CDH17) achieved superior tumor growth inhibition compared to EGFR- or c-MET/EGFR-targeting antibodies while reducing skin-related toxicities in preclinical colorectal cancer studies. The

Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC Research published in JCO Precision Oncology explores how relative mutant allele frequency in circulating tumor DNA (ctDNA) could help determine when to rechallenge patients with anti-EGFR therapy after resistance develops.

Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google

Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era

Skip to content The CRC Digest Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era A narrative review evaluates clinical integration of BRAF-targeted therapy combined with EGFR inhibition, addressing first-line treatment, MMR/MSI status, patient fitness, and sequencing strategies. (J Gastrointest Cancer) This content is informational only and

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC A phase 1b/2 trial found that ifebemtinib plus garsorasib demonstrated anticancer activity and manageable safety in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer, though the improvement in response rate did not

Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC The DEEPER trial presents final analysis of long-term survival outcomes comparing modified-FOLFOXIRI plus cetuximab versus bevacizumab in patients with RAS and BRAF wild-type metastatic colorectal cancer. (Journal of Clinical Oncology) This

Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer Pooled analysis of 180 patients from the CAVE and CAVE-2 studies investigates clinical variables that predict response to cetuximab rechallenge (with or without avelumab) in patients with circulating tumor DNA RAS/

HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance

Skip to content The CRC Digest ▸ TREATMENT HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance Narrative review outlines practical patient selection and treatment sequencing for HER2-targeted therapies in metastatic colorectal cancer, focusing on RAS wild-type disease with HER2 overexpression or ERBB2 amplification, including dual HER2